Institute of Experimental Biology, Faculty of Science, Masaryk University, Kotlarska 267/2, Brno, Czech Republic.
Department of Medical Genetics, University Hospital Brno, Cernopolni 212/9, Brno, Czech Republic.
BMC Med Genomics. 2019 Jul 23;12(1):111. doi: 10.1186/s12920-019-0559-7.
Chromosomal microarray analysis has been shown to be a valuable and cost effective assay for elucidating copy number variants (CNVs) in children with intellectual disability and developmental delay (ID/DD).
In our study, we performed array-based comparative genomic hybridization (array-CGH) analysis using oligonucleotide-based platforms in 542 Czech patients with ID/DD, autism spectrum disorders and multiple congenital abnormalities. Prior to the array-CGH analysis, all the patients were first examined karyotypically using G-banding. The presence of CNVs and their putative derivation was confirmed using fluorescence in situ hybridization (FISH), multiplex ligation-dependent probe amplification (MLPA) and predominantly relative quantitative polymerase chain reaction (qPCR).
In total, 5.9% (32/542) patients were positive for karyotypic abnormalities. Pathogenic/likely pathogenic CNVs were identified in 17.7% of them (96/542), variants of uncertain significance (VOUS) were detected in 4.8% (26/542) and likely benign CNVs in 9.2% of cases (50/542). We identified 6.6% (36/542) patients with known recurrent microdeletion (24 cases) and microduplication (12 cases) syndromes, as well as 4.8% (26/542) patients with non-recurrent rare microdeletions (21 cases) and microduplications (5 cases). In the group of patients with submicroscopic pathogenic/likely pathogenic CNVs (13.3%; 68/510) we identified 91.2% (62/68) patients with one CNV, 5.9% (4/68) patients with two likely independent CNVs and 2.9% (2/68) patients with two CNVs resulting from cryptic unbalanced translocations. Of all detected CNVs, 21% (31/147) had a de novo origin, 51% (75/147) were inherited and 28% (41/147) of unknown origin. In our cohort pathogenic/likely pathogenic microdeletions were more frequent than microduplications (69%; 51/74 vs. 31%; 23/74) ranging in size from 0.395 Mb to 10.676 Mb (microdeletions) and 0.544 Mb to 8.156 Mb (microduplications), but their sizes were not significantly different (P = 0.83). The pathogenic/likely pathogenic CNVs (median 2.663 Mb) were significantly larger than benign CNVs (median 0.394 Mb) (P < 0.00001) and likewise the pathogenic/likely pathogenic CNVs (median 2.663 Mb) were significantly larger in size than VOUS (median 0.469 Mb) (P < 0.00001).
Our results confirm the benefit of array-CGH in the current clinical genetic diagnostics leading to identification of the genetic cause of ID/DD in affected children.
染色体微阵列分析已被证明是一种有价值且具有成本效益的方法,可阐明智力障碍和发育迟缓(ID/DD)儿童的拷贝数变异(CNVs)。
在我们的研究中,我们使用基于寡核苷酸的平台在 542 名捷克 ID/DD、自闭症谱系障碍和多发性先天性异常患者中进行了基于阵列的比较基因组杂交(array-CGH)分析。在进行 array-CGH 分析之前,所有患者首先使用 G 带进行核型分析。使用荧光原位杂交(FISH)、多重连接依赖性探针扩增(MLPA)和主要相对定量聚合酶链反应(qPCR)确认 CNVs 的存在及其潜在来源。
总共有 5.9%(32/542)的患者存在核型异常。在其中 17.7%(96/542)的患者中发现了致病性/可能致病性 CNVs、不确定意义的变异(VOUS)在 4.8%(26/542)的患者中检测到,9.2%(50/542)的患者存在可能良性的 CNVs。我们确定了 6.6%(36/542)的患者存在已知的复发性微缺失(24 例)和微重复(12 例)综合征,以及 4.8%(26/542)的患者存在非复发性罕见微缺失(21 例)和微重复(5 例)。在亚显微镜致病性/可能致病性 CNVs(13.3%;68/510)的患者组中,我们发现 91.2%(62/68)的患者存在一个 CNV,5.9%(4/68)的患者存在两个可能独立的 CNV,2.9%(2/68)的患者存在两个来自隐匿性不平衡易位的 CNV。所有检测到的 CNVs 中,21%(31/147)为新生起源,51%(75/147)为遗传起源,28%(41/147)为未知起源。在我们的队列中,致病性/可能致病性微缺失比微重复更常见(69%;51/74 与 31%;23/74),大小范围从 0.395Mb 到 10.676Mb(微缺失)和 0.544Mb 到 8.156Mb(微重复),但它们的大小没有显著差异(P=0.83)。致病性/可能致病性 CNVs(中位数 2.663Mb)明显大于良性 CNVs(中位数 0.394Mb)(P<0.00001),致病性/可能致病性 CNVs(中位数 2.663Mb)也明显大于 VOUS(中位数 0.469Mb)(P<0.00001)。
我们的结果证实了 array-CGH 在当前临床遗传诊断中的益处,导致确定受影响儿童 ID/DD 的遗传原因。